Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma

Molecular Cancer Therapeutics

Volumn 8, Issue 2, 2009, Pages 415-423

  Lam, Wing ^a   Bussom, Scott ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CELL NUCLEUS DNA; DEOXYCYTIDINE KINASE; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; LUCIFERASE; PHOSPHOGLYCERATE KINASE; PIMONIDAZOLE; TROXACITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL HYPOXIA; CLONOGENESIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; CYTOSINE; DEOXYCYTIDINE; DIOXOLANES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMICS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; PHOSPHOGLYCERATE KINASE; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 60849131878     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0692     Document Type: Article

References (25)

1. Kim HO, Ahn SK, Alves AJ, et al. Asymmetric synthesis of 1, 3- dioxolane-pyrimidine nucleosides and their anti-HIV activity. J Med Chem 1992;35:1987-95.
2. Grove KL, Cheng YC. Uptake and metabolism of the new anticancer compound β-l-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res 1996;56:4187-91.
3. Grove KL, Guo X, Liu SH, Gao Z, Chu CK, Cheng YC. Anticancer activity of β-l-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res 1995;55:3008-11.
4. Gourdeau H, Leblond L, Hamelin B, et al. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development. Clin Cancer Res 2004;10:7692 - 702.
5. Giles FJ, Garcia-Manero G, Cortes JE, et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 2002;20:656 - 64.
6. Lapointe R, Letourneau R, Steward W, et al. Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors. Ann Oncol 2005;2:289 - 93.
7. Townsley CA, Chi K, Ernst DS, et al. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2003;21:1524- 9.
8. Dent SF, Arnold A, Stewart DJ, et al. Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer. Lung 2005;183:265 - 72.
9. Gourdeau H, Clarke ML, Ouellet F, et al. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res 2001;61:7217 - 24.
10. Kukhanova M, Liu SH, Mozzherin D, Lin TS, Chu CK, Cheng YC. L and D-Enantiomers of 2′, 3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNApolymerases. Implications for the mechanism of toxicity. J Biol Chem 1995;270:23055 - 9.
11. Krishnan P, Fu Q, Lam W, Liou JY, Dutschman G, Cheng YC. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3- phosphoglycerate kinase. J Biol Chem 2002;277:5453 - 9.
12. Krishnan P, Gullen EA, Lam W, Dutschman GE, Grill SP, Cheng YC. Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents. J Biol Chem 2003;278:36726 - 32.
13. Krishnan P, Liou JY, Cheng YC. Phosphorylation of pyrimidine L-deoxynucleoside analog diphosphates. Kinetics of phosphorylation and dephosphorylation of nucleoside analog diphosphates and triphos- phates by 3-phosphoglycerate kinase. J Biol Chem 2002;277:31593 - 600.
14. Chou KM, Kukhanova M, Cheng YC. Anovel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribo- nucleoside analogs from the 3′ termini of DNA. J Biol Chem 2000;275:31009 - 15.
15. Lam W, Park SY, Leung CH, Cheng YC. Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and β-L-2′, 3′-dideoxy- 2′, 3′-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcitabine and β-D-arabinofuranosylcytosine). Mol Pharmacol 2006;69:1607 - 14.
16. Lam W, Leung CH, Bussom S, Cheng YC. The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine. Mol Pharmacol 2007;72:536 - 44.
17. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437 - 47.
18. Liou JY, Dutschman GE, Lam W, Jiang Z, Cheng YC. Characterization of human UMP/CMP kinase and its phosphorylation of D-and L-form deoxycytidine analogue monophosphates. Cancer Res 2002;62:1624- 31.
19. Hatzis P, Al-Madhoon AS, Jullig M, Petrakis TG, Eriksson S, Talianidis I. The intracellular localization of deoxycytidine kinase. J Biol Chem 1998; 273:30239 - 43.
20. Weitman S, Marty J, Jolivet J, Locas C, Von Hoff DD. The new dioxolane, (-)-2′-deoxy-3′-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin Cancer Res 2000;6:1574- 8.
21. Kadhim SA, Bowlin TL, Waud WR, et al. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (β-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res 1997;57:4803 - 10.
22. Damaraju VL, Bouffard DY, Wong CK, et al. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer. BMC Cancer 2007;7:121.
23. Swords R, Apostolidou E, Giles F. Troxacitabine in leukemia. Hematology 2006;11:321 - 9.
24. Quintas-Cardama A, Cortes J. Evaluation of the l-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia. Expert Opin Investig Drugs 2007;16:547 - 57.
25. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006;12:7215 - 20.